Search

GI Cancer ESMO 2024 Highlights: Key Studies Discussed LEAP-012, KEYNOTE-811, POD1UM-303, NICHE-2


Key points:

Pastel Blue Pastel Pink Soft Gradients & Gloss Self-help Podcast Cover 1235
  • LEAP-012 Study: An update on HCC treatment with Lenvatinib and Pembrolizumab combined with TACE
  • KEYNOTE-811: Highlighting improved OS with Pembrolizumab, chemotherapy, and Trastuzumab in HER2+ GEJ/Gastric adenocarcinoma
  • POD1UM-303 Trial: OS improvement with the addition of the PD-1 inhibitor Retifanlimab to chemotherapy in metastatic anal cancer
  • NICHE-2 Study: MSI-high patients, showcasing a 100% three-year disease-free survival rate with neoadjuvant immunotherapy

In this episode of the Oncology Brothers podcast, we had the pleasure of discussing the highlights from ESMO 2024, specifically focusing on gastrointestinal malignancies. Drs. Rohit and Rahul Gosain were joined by Dr. Kristen Ciombor, a GI medical oncologist from Vanderbilt University, who guided through four key studies that have significant implications for our clinical practice.

The discussion began with the LEAP-012 study, which explored the combination of Lenvatinib and Pembrolizumab with TACE in patients with hepatocellular carcinoma (HCC). While the study showed promising progression-free survival (PFS) results, we emphasized the need for mature overall survival (OS) data before making any firm conclusions about its potential to replace current standard care.

Next, we delved into the KEYNOTE-811 study, which has established itself as a standard of care for HER2-positive gastroesophageal junction and gastric adenocarcinoma patients. Dr. Ciombor highlighted the improved OS data with Pembrolizumab combined with chemotherapy and Trastuzumab, reinforcing its role in our treatment protocols, especially for patients with positive PD-L1 status.

We then discussed the POD1UM-303 trial, a significant study in metastatic anal cancer, which demonstrated a statistically significant improvement in PFS with the addition of the PD-1 inhibitor Retifanlimab to chemotherapy. This study is poised to change the standard of care for this challenging disease.

Finally, we explored the NICHE-2 study, which has shown remarkable results for MSI-high patients, reporting a 100% three-year disease-free survival rate with a short course of immunotherapy. Dr. Ciombor shared her insights on the implications of this data and the ongoing questions regarding treatment decisions based on ctDNA results.

Overall, this episode provided valuable insights into the latest advancements in GI oncology, and we are excited to see how these studies will shape our clinical practices moving forward. Thank you for tuning in, and we look forward to sharing more updates and discussions in future episodes!